067080 — Dae Hwa Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Dae Hwa Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	114,610	109,346	117,159	131,912	141,359
Cost of Revenue
Gross Profit	48,630	42,770	43,673	46,099	45,406
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	109,510	106,528	115,965	129,099	139,696
Operating Profit	5,099	2,818	1,194	2,812	1,663
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	14,319	-796	4,525	2,426	-456
Provision for Income Taxes
Net Income After Taxes	9,072	-2,483	1,962	1,221	-514
Minority Interest
Net Income Before Extraordinary Items
Net Income	10,541	-2,008	2,217	1,116	-1,147
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10,541	-2,008	2,217	1,116	-1,147
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	638	-79.1	175	147	-59.1
Dividends per Share